Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.80 1.22% 149.90 150.50 150.80 151.20 146.40 146.40 301,731 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 473.2 -126.5 -14.6 - 1,100

Indivior Share Discussion Threads

Showing 3501 to 3524 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
09/9/2020
12:31
It's the electric chair for him then.......
meijiman
05/9/2020
18:15
RNS Number : 1399Y Indivior PLC 04 September 2020 September 4, 2020 Indivior PLC - Board Announcement Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect. Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor. Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 ( bio ). He is a member of the Audit and Remuneration Committees.
grupo
04/9/2020
18:37
Fri, 4th Sep 2020 17:31 RNS Number : 1399Y Indivior PLC 04 September 2020 September 4, 2020 Indivior PLC - Board Announcement Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect. Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor. Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 (bio). He is a member of the Audit and Remuneration Committees. Investor Contact: Jason Thompson, IndiviorVice President, Investor Relations+1 804-402-7123Jason.Thompson@indivior.com
ariane
02/9/2020
20:38
FTSE 250 Adds: Indivior
adrian j boris
01/9/2020
10:21
Newtyn Management, LLC New York, United States Just bought near 4pc
sarkasm
31/8/2020
08:38
THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 90 to 100p 110 to 120p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 120 to 130p 130 to 140p 140 to 150p 150 to 160p 160 to 170pCiti target 165p 170 to 180p 180 to 190p 190 to 200p Jefferies target 200p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again June ends in the 80 to 90p BOX at 83p July ends at 137.60p August ends at 118.70p current strong support seems to be 111p current strong resistence seems to be 142.40p
waldron
29/8/2020
20:04
Https://scientect.com/uncategorized/839280/global-opioid-use-disorder-market-is-thriving-worldwide-with-indivior-plc-teva-pharmaceutical-industries-ltd-omeros-corporation-camurus-hikma-pharmaceuticals-plc/
waldron
28/8/2020
07:48
It seems theres possible strong support at 111p
waldron
26/8/2020
17:54
The Department of Justice’s (“DOJ”) $600 million civil and criminal settlement against Indivior related to marketing the opioid-addiction-treatment drug Suboxone, combined with the prior, larger, $1.4 billion settlement with Reckitt Benckiser Group PLC, Indivior’s former parent company, inked in 2019 yield longer term shareholder standing in potential derivative matters. These matters seek to enhance corporate governance and go after D&O policies to get funds paid in fines back into corporate coffers. Can also allow for incentive awards to shareholders. Best, Josh jgrabar@grabarlaw.com https://www.justice.gov/opa/pr/justice-department-obtains-14-billion-reckitt-benckiser-group-largest-recovery-case https://www.justice.gov/opa/pr/opioid-manufacturer-indivior-s-chief-executive-officer-pleads-guilty-connection-drug-safety
jgrabar
26/8/2020
08:04
Https://www.jdsupra.com/legalnews/doj-demonstrates-continued-focus-on-47501/ August 25, 2020 DOJ Demonstrates Continued Focus on Opioid Crisis with $600 Million Criminal and Civil Settlement Against Indivior Solutions, Indivior Inc., and Indivior plc Dorsey & Whitney LLP The Department of Justice’s (“DOJ”) most recent settlement with Indivior Solutions, Inc., Indivior Inc., and Indivior plc (together, “Indivior”) demonstrates not only that the DOJ is continuing its pursuit of claims and settlements related to the opioid crisis, but also that the DOJ is searching for creative penalties beyond large monetary payouts. In a July 24, 2020 press release, the DOJ announced a $600 million civil and criminal settlement against Indivior related to marketing the opioid-addiction-treatment drug Suboxone. This settlement follows a larger, $1.4 billion settlement with Rickeitt Benckiser Group PLC, Indivior’s former parent company, inked in 2019. The DOJ touts the combined $2 billion value of the 2019 and 2020 settlements as the largest-ever resolution in a case brought by the DOJ involving opioid drugs. The civil settlement resolves claims from six qui tam lawsuits brought against various combinations of the Indivior entities under the False Claims Act (“FCA”). United States ex rel. Finkelstein v. Reckitt Benckiser Pharms., Inc., No. 14-cv-00059 (W.D. Va.); United States ex rel. Williams v. Reckitt Benckiser, Inc., No. 13-cv-00036 (W.D. Va.); United States ex rel. Lemons v. Reckitt Benckiser Pharms., No. 15-cv-00016 (W.D. Va.); United States ex rel. Kruszewski v. Reckitt Benckiser Pharms., Inc., No. XX-cv-XXXX [UNDER SEAL] (D.N.J.); United States ex rel. Scott v. Reckitt Benckiser Pharms, Inc., No. XX-cv-XXXX [UNDER SEAL] (N.D.J.); United States ex rel. Greene v. Indivior PLC, No. XX-cv-XXXX [UNDER SEAL] (D.N.J.). Under the civil settlement, Indivior Inc. and Indivior plc agreed to pay $300 million, with $209.3 million going to the federal government and $90.7 million going to certain participating states. The amount awarded to the individual whistleblowers has yet to be determined. While Indivior did not admit fault in its civil settlement, the settlement resolves three main allegations. First, the DOJ alleged Indivior knowingly promoted the sale and use of Suboxone to physicians who were writing prescriptions not for a medically-accepted indication, lacked a legitimate medical purpose, were issued without counseling or psychosocial support, were for unsafe, ineffective, and medically-unnecessary uses, or were often diverted. Second, the DOJ alleged that Indivior knowingly promoted the sale or use of Suboxone Film to physicians and state Medicaid agencies using false and misleading claims that Suboxone Film was less susceptible to accidental pediatric exposure than Suboxone Tablets. And third, the DOJ alleged that Indivior tried to delay the entry of generic competition to control the price of Suboxone—including pricing to federal healthcare programs. Such actions allegedly included the improper submission of a petition to the Food and Drug Administration (“FDA”) claiming that Suboxone Tablet had been discontinued “due to safety concerns” about the tablet formulation of the drug. As part of the criminal resolution, Indivior Solutions pleaded guilty to a one-count felony criminal information charging false statements related to health care matters, in violation of 18 U.S.C. § 1035. See United States v. Indivior Solutions, Inc., 19-cr-00016-JPJ-PMS (W.D. Va.). The plea included an admission that Indivior Solutions made false statements to promote the film version of Suboxone to the Massachusetts Medicaid programs regarding the safety of Suboxone Film around children. The settlement includes a criminal fine, forfeiture, and restitution in the combined amount of $289 million. The criminal resolution also includes novel, non-monetary components, requiring that Indivior Inc. permanently disband its entire Suboxone sales force and a prohibition from using data obtained from surveys of health care providers for marketing, sales, or proposal purposes. Indivior’s CEO will also be required to annually certify—under penalty of perjury—either that: (1) Indivior was complaint with the Food, Drug, and Cosmetic Act and did not commit health care fraud; or (2) list all of Indivior’s non-compliant activity and the steps taken to remedy it. Finally, Indivior Inc. is also required to remove health care providers from its promotion programs at high risk of inappropriate prescribing. Neither the press release nor settlement materials explain how Indivior is supposed to identify high-risk providers. Failure to meet the above requirements will cause contempt sanctions and a reinstatement of the dismissed charges. Besides the civil and criminal settlements, Indivior also agreed to a five-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General, under which Indivior will implement numerous accountability and auditing provisions, including a yearly compliance certification by Indivior executives and Board of Directors, annual risk assessments and other monitoring, and multi-faceted audits conducted by an independent review organization. These cases serve as a reminder that the DOJ continues to aggressively pursue both civil and criminal claims related to the opioid crisis and provides insight into the non-monetary, compliance-based penalties the DOJ may pursue as part of global civil and criminal resolutions. As the stated by Elton Malone, Assistant Inspector General for Investigations with the Office of Inspector General of the U.S. Department of Health and Human Services, “[t]his resolution, along with our law enforcement partners’ work, should serve as a warning that large companies will face prosecution if they break the law.”
sarkasm
26/8/2020
08:03
Https://www.competitionpolicyinternational.com/judge-allows-additional-antitrust-claims-in-indivior-dispute/ Judge Allows Additional Antitrust Claims In Indivior Dispute CPI - August 25, 2020 law A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
sarkasm
25/8/2020
17:26
Seemed bullish on 'good data' over coming years
the stigologist
25/8/2020
16:44
The company also noted Indivior PLC has started a Phase 1 clinical trial for C4X's novel selective Orexin-1 antagonist, for the treatment of opioid dependence with the first patient now dosed. The study is expected to complete by year end.
waldron
25/8/2020
15:30
C4X Discovery Joins Covid Collaboration With Italian Hospitals Tue, 25th Aug 2020 12:28 (Alliance News) - Drug discovery firm C4X Discovery Holdings PLC said Tuesday it has entered into a new collaboration with the GEN-COVID consortium, a network of more than 20 hospitals in Italy. "The collaboration will use the unique mathematical genetic analysis methodology of Taxonomy3 to investigate the role genetics plays in the widely varied disease susceptibility, severity and prognosis observed between individuals with Covid-19," C4X explained. Taxonomy3 will analyse genetic data from a "significant" number of Covid-19 positive patients collected by the consortium to identify genes associated with severe Covid-19 disease, the drug discovery firm said. C4X added: "The aim is to identify a unique genetic signature that can successfully predict mild versus severe disease to inform treatment of patients at risk. The analysis may also uncover novel biology driving severity of the disease which may inform potential novel drug targets for treatment." Chief Executive Clive Dix said: "The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. "We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis. This is a new area for C4XD and we are excited to be working on such an important project. We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development." The company also noted Indivior PLC has started a Phase 1 clinical trial for C4X's novel selective Orexin-1 antagonist, for the treatment of opioid dependence with the first patient now dosed. The study is expected to complete by year end. Dix continued: "I am delighted to share the progress we have made over recent months across our proprietary portfolio despite the challenges of the Covid-19 pandemic, in particular, the continued headway in our key inflammation programmes. "Our two most advanced programmes, NRF-2 and IL-17, continue to move forward with one of our lead NRF-2 molecules, C4X_6746, showing significant efficacy in a pre-clinical model of Inflammatory Bowel Disease. This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for Pulmonary Arterial Hypertension and Sickle Cell Disease." Shares in C4X Discovery were down 9.2% in London on Tuesday at 22.25 pence each. By Paul McGowan; paulmcgowan@alliancenews.com
waldron
10/8/2020
10:19
Aggregate of Standard Life Aberdeen plc affiliated investment management entities with delegated voting rights on behalf of multiple managed portfolios City and country of registered office Edinburgh, Scotland ONLY A SLIGHT REDUCTION IN HOLDING
waldron
08/8/2020
08:47
THE WISH LIST 90 to 100p 110 to 120p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 120 to 130p 130 to 140p 140 to 150p 150 to 160p 160 to 170pCiti target 165p 170 to 180p 180 to 190p 190 to 200p Jefferies target 200p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again June ends in the 80 to 90p BOX at 83p July ends at 137.60p current strong support seems to be 106p current strong resistence seems to be 142.40p The week ends at 119.50p
waldron
05/8/2020
17:08
Price (GBX) 121.50 -7.74%
sarkasm
04/8/2020
17:53
Price (GBX) 131.70 -4.91% Open / Last close 137.30 / 131.70 High / Low 139.40 / 130.50 Bid / Offer 132.00 / 132.70
the grumpy old men
31/7/2020
20:30
THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 90 to 100p 110 to 120p 120 to 130p 130 to 140p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 140 to 150p 150 to 160p 160 to 170pCiti target 165p 170 to 180p 180 to 190p 190 to 200p Jefferies target 200p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again June ends in the 80 to 90p BOX at 83p July ends at 137.60p current strong support seems to be 98.40p current strong resistence seems to be 184.20p
waldron
30/7/2020
17:23
Well I finally heard the on line presentation later this afternoon and overall I felt relatively good about it. The presentation sounded positive and struck the right note in the context that the DOJ deal is not yet done/signed off,. Interestingly, Indivior is keeping to the 1 billion dollar Sublocade revenue target whilst Perseris sounded as if it was moving in the right direction in sales and potential. So, I am happy ( well happier than I have been, make no mistake !)to wait for further recovery.
gregmorg
30/7/2020
16:27
Alexander Bueso Sharecast News 30 Jul, 2020 12:08 30 Jul, 2020 12:08 Indivior 1H profits reduced by nearly three quarters amid pandemic Indivior suffered a precipitous drop in sales and profits over the first half as the Covid-19 pandemic saw the number of new patients in the US for its anti-opioid addiction drug dry up. Net revenues declined by 30% at constant exchange rates to reach $150.0m, for a 75% decline in net income to $18m. Also on a CER basis meanwhile, its earnings per share collapsed by 75% from 10.0p to 2.0p. Company chief executive officer, Mark Crossley highlighted the performance of its Sublocade treatment for opioid withdrawal, saying he was encouraged by stable sales of $29m for the product, which were unchanged in comparison to the prior three-month period. While conceding that the company, like the rest of the industry, was continuing to be impacted by a reduced number of new patients in the US, he expressed optimism over the outlook for Sublocade and its schizophrenia therapy, Perseris. To take note of, just two days before the company reached a settlement with US authorities regarding charges that it engaged in an illicit arrangement across the US to boost prespcriptions of its previously block-buster opioid addiction drug, Suboxone Film. Shaun Thaxter, Indivior's prior CEO, resigned earlier in July before pleading guilty to one misdemeanour count of mis-representing the safety of Suboxone Film for recovering addicts. Sublocade did however win regulatory approval in Sweden and the European Union earlier in 2020. Despite having removed, according to some analysts, the overhang from potential litigation costs, the company's sales remained well below the more than $1.0bn reached in 2018, when Suboxone Film lost its patent protection in the US. As of 1204 BST, shares of Indivior were 1.7% stronger to 137.8p.
waldron
30/7/2020
16:23
Indivior in the red as opioid addiction treatment continues to lose market share to generics By BFN News | 08:54 AM | Thursday 30 July, 2020 Factsheet Indivior Plc Ord USD0.10 (INDV) Pharmaceutical company Indivior swung to a loss in the first half of the year after revenue declined by a third as the company's Suboxone film continue to lose market share to generics. For the six months ended 30 June, the company reported a pre-tax loss of $145m, compared with a profit of $163m on-year as revenue fell 33% to $303m. Suboxone film market share during H1 2020 averaged 22%, down from 38% on-year. Suboclade revenue jumped to $58m from $28m. Looking ahead, the company warned of a 'significant' reduction in Suboxone film revenue as a result of market share loss 'reaching historical industry analogues and negative channel mix.' Suboclade, meanwhile, was expected to see 'modest' growth in new patient enrollments compared with Q2 exit levels, it added. At 8:54am: (LON:INDV) Indivior Plc share price was +2p at 137.5p Story provided by StockMarketWire.com
waldron
30/7/2020
07:39
More positive news. 200p today?
hodhasharon
30/7/2020
07:37
Well,the company seem pleased enough with their performance.Meeting should be enlightening.I note that the company's net cash position tallies conveniently with the sum demanded by the D of J.Probably just a coincidence.
steeplejack
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210517 18:50:16